Login
Companies $PRLD
$3.35 -$0.06 (1.76%) After hours
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc

preludetx.com

What Do They Do?

Develops targeted cancer drug candidates for patients with underserved cancers, using inhibitors, protein degraders and antibody-linked drugs.

How Do They Make Money?

Prelude receives upfront payments under program option and license agreements; agreements can also provide clinical and regulatory milestone payments and royalties on product sales.

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $99.5M in FY2025.

Operating income, FY2025
−861% of revenue
▲ +25% (Loss) vs FY2024 (−$139.7M, −1996%)
Net income, FY2025
−820% of revenue
▲ +22% (Loss) vs FY2024 (−$127.2M, −1817%)
Free cash flow, FY2025
−464% of revenue
▲ +46% (Loss) vs FY2024 (−$103.7M, −1481%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −13%
vs $6.5M in Q3 FY2025
Net income
▲ +36% (Loss)
vs −$19.7M in Q3 FY2025

Pipeline focus The older report describes programs spanning methyltransferases and protein-protein interactions; the latest emphasizes kinases, targeted protein degraders and degrader antibody conjugates.

Who Do They Compete With?

Competes with Ajax Therapeutics, Atavistik Bio, Cogent Biosciences, Eilean Therapeutics, Incyte, Llydlaw Therapeutics, Rathyra Therapeutics, V6 Therapeutics, Pfizer, Olema Oncology, Menarini Group, BeOne Medicines, Ideaya Biosciences, Isosterix, ProtAI, and Beijing Konruns Pharmaceutical

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support